A sting in the tail: The N-terminal domain of the androgen receptor as a drug target

Asian Journal of Andrology

Volumn 18, Issue 5, 2016, Pages 687-694

  Monaghan, Amy E ^a   McEwan, Iain J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

androgen receptor; inhibitor; intrinsically disordered structure; N terminal domain; prostate cancer; small molecules

Indexed keywords

ANDROGEN RECEPTOR; NATURAL PRODUCT; SELECTIVE ANDROGEN RECEPTOR MODULATOR; ANDROGEN RECEPTOR ANTAGONIST;

ALTERNATIVE RNA SPLICING; AMINO TERMINAL DOMAIN; AMINO TERMINAL SEQUENCE; ANTIANDROGEN THERAPY; CASTRATION RESISTANT PROSTATE CANCER; DRUG TARGETING; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; DISEASE COURSE; MALE; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; TRANSCRIPTION INITIATION;

ANDROGEN RECEPTOR ANTAGONISTS; DISEASE PROGRESSION; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSCRIPTIONAL ACTIVATION;

EID: 84983741973     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.181081     Document Type: Review

References (65)

1. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer 2002; 2: 389-96.
2. Haendler B, Cleve A. Recent developments in antiandrogens and selective androgen receptor modulators. Mol Cell Endocrinol 2012; 352: 79-91.
3. Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov 2013; 3: 1020-9.
4. McDonald S, Brive L, Agus DB, Scher HI, Ely KR. Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. Cancer Res 2000; 60: 2317-22.
5. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008; 68: 5469-77.
6. Guo Z, Yang X, Sun F, Jiang R, Linn DE, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009; 69: 2305-13.
7. Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, et al. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem 2005; 48: 2972-84.
8. Brooke GN, Powell SM, Lavery DN, Waxman J, Buluwela L, et al. Engineered repressors are potent inhibitors of androgen receptor activity. Oncotarget 2014; 5: 959-69.
9. Gustafson JL, Neklesa TK, Cox CS, Roth AG, Buckley DL, et al. Small-molecule-mediated degradation of the androgen receptor through hydrophobic tagging. Angew Chem Int Ed Engl 2015; 54: 9659-62.
10. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010; 17: 535-46.
11. Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, et al. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. J Biol Chem 2014; 289: 26417-29.
12. Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, et al. International union of pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev 2006; 58: 782-97.
13. Davison SL, Bell R. Androgen physiology. Semin Reprod Med 2006; 24: 71-7.
14. Sinnesael M, Claessens F, Laurent M, Dubois V, Boonen S, et al. Androgen receptor (AR) in osteocytes is important for the maintenance of male skeletal integrity: evidence from targeted AR disruption in mouse osteocytes. J Bone Miner Res 2012; 27: 2535-43.
15. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61: 4315-9.
16. Gibson DA, Simitsidellis I, Collins F, Saunders PT. Evidence of androgen action in endometrial and ovarian cancers. Endocr Relat Cancer 2014; 21: T203-18.
17. Rodriguez-Gonzalez A, Cyrus K, Salcius M, Kim K, Crews CM, et al. Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer. Oncogene 2008; 27: 7201-11.
18. Brinkmann AO, Faber PW, van Rooij HC, Kuiper GG, Ris C, et al. The human androgen receptor: domain structure, genomic organization and regulation of expression. J Steroid Biochem 1989; 34: 307-10.
19. Trapman J, Klaassen P, Kuiper GG, van der Korput JA, Faber PW, et al. Cloning, structure and expression of a cDNA encoding the human androgen receptor. Biochem Biophys Res Commun 1988; 153: 241-8.
20. Gottlieb B, Beitel LK, Nadarajah A, Paliouras M, Trifiro M. The androgen receptor gene mutations database: 2012 update. Hum Mutat 2012; 33: 887-94.
21. Clinckemalie L, Vanderschueren D, Boonen S, Claessens F. The hinge region in androgen receptor control. Mol Cell Endocrinol 2012; 358: 1-8.
22. Cutress ML, Whitaker HC, Mills IG, Stewart M, Neal DE. Structural basis for the nuclear import of the human androgen receptor. J Cell Sci 2008; 121: 957-68.
23. Helsen C, Dubois V, Verfaillie A, Young J, Trekels M, et al. Evidence for DNA-binding domain-Ligand-binding domain communications in the androgen receptor. Mol Cell Biol 2012; 32: 3033-43.
24. Haelens A, Tanner T, Denayer S, Callewaert L, Claessens F. The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. Cancer Res 2007; 67: 4514-23.
25. Simental JA, Sar M, Lane MV, French FS, Wilson EM. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 1991; 266: 510-8.
26. Jenster G, van der Korput HA, Trapman J, Brinkmann AO. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem 1995; 270: 7341-6.
27. Kumar R, McEwan IJ. Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation. Endocr Rev 2012; 33: 271-99.
28. Lavery DN, McEwan IJ. Functional characterization of the native NH2-terminal transactivation domain of the human androgen receptor: binding kinetics for interactions with TFIIF and SRC-1a. Biochemistry 2008; 47: 3352-9.
29. Wilson EM. Primate-specific multi-functional androgen receptor coregulator and proto-oncogene melanoma antigen-A11 (MAGE-A11). In: McEwan IJ, Kumar R, editors. Nuclear Receptors: From Structure to the Clinic. Switzerland: Springer; 2015. p. 137.
30. Brodie J, McEwan IJ. Intra-domain communication between the N-terminal and DNA-binding domains of the androgen receptor: modulation of androgen response element DNA binding. J Mol Endocrinol 2005; 34: 603-15.
31. Dar JA, Masoodi KZ, Eisermann K, Isharwal S, Ai J, et al. The N-terminal domain of the androgen receptor drives its nuclear localization in castration-resistant prostate cancer cells. J Steroid Biochem Mol Biol 2014; 143: 473-80.
32. Davies P, Watt K, Kelly SM, Clark C, Price NC, et al. Consequences of poly-glutamine repeat length for the conformation and folding of the androgen receptor amino-terminal domain. J Mol Endocrinol 2008; 41: 301-14.
33. Lavery DN, McEwan IJ. Structural characterization of the native NH2-terminal transactivation domain of the human androgen receptor: a collapsed disordered conformation underlies structural plasticity and protein-induced folding. Biochemistry 2008; 47: 3360-9.
34. McEwan IJ. Intrinsic disorder in the androgen receptor: identification, characterisation and drugability. Mol Biosyst 2012; 8: 82-90.
35. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010; 120: 2715-30.
36. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 2011; 6: e19059.
37. Cao B, Qi Y, Zhang G, Xu D, Zhan Y, et al. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget 2014; 5: 1646-56.
38. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 371: 1028-38.
39. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 2012; 72: 3457-62.
40. Krause WC, Shafi AA, Nakka M, Weigel NL. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. Int J Biochem Cell Biol 2014; 54: 49-59.
41. Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011; 71: 6019-29.
42. Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res 2014; 74: 2270-82.
43. Meimetis LG, Williams DE, Mawji NR, Banuelos CA, Lal AA, et al. Niphatenones, glycerol ethers from the sponge Niphates digitalis block androgen receptor transcriptional activity in prostate cancer cells: structure elucidation, synthesis, and biological activity. J Med Chem 2012; 55: 503-14.
44. Sadar MD, Williams DE, Mawji NR, Patrick BO, Wikanta T, et al. Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells. Org Lett 2008; 10: 4947-50.
45. Takeuchi T, Tsutsumi O. Serum bisphenol a concentrations showed gender differences, possibly linked to androgen levels. Biochem Biophys Res Commun 2002; 291: 76-8.
46. Takeuchi T, Tsutsumi O, Ikezuki Y, Takai Y, Taketani Y. Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. Endocr J 2004; 51: 165-9.
47. Ye L, Zhao B, Hu G, Chu Y, Ge RS. Inhibition of human and rat testicular steroidogenic enzyme activities by bisphenol A. Toxicol Lett 2011; 207: 137-42.
48. Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, et al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest 2013; 123: 2948-60.
49. Brand LJ, Olson ME, Ravindranathan P, Guo H, Kempema AM, et al. EPI-001 is a selective peroxisome proliferator-Activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget 2015; 6: 3811-24.
50. Martin SK, Banuelos CA, Sadar MD, Kyprianou N. N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy. Mol Oncol 2015; 9: 628-39.
51. Banuelos CA, Lal A, Tien AH, Shah N, Yang YC, et al. Characterization of niphatenones that inhibit androgen receptor N-terminal domain. PLoS One 2014; 9: e107991.
52. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013; 155: 1309-22.
53. Ravindranathan P, Lee TK, Yang L, Centenera MM, Butler L, et al. Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nat Commun 2013; 4: 1923.
54. Quayle SN, Mawji NR, Wang J, Sadar MD. Androgen receptor decoy molecules block the growth of prostate cancer. Proc Natl Acad Sci U S A 2007; 104: 1331-6.
55. Bradbury RH, Hales NJ, Rabow AA, Walker GE, Acton DG, et al. Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer. Bioorg Med Chem Lett 2011; 21: 5442-55.
56. Bradbury RH, Acton DG, Broadbent NL, Brooks AN, Carr GR, et al. Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer. Bioorg Med Chem Lett 2013; 23: 1945-58.
57. Loddick SA, Ross SJ, Thomason AG, Robinson DM, Walker GE, et al. AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther 2013; 12: 1715-27.
58. Omlin A, Jones RJ, van der Noll R, Satoh T, Niwakawa M, et al. AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer-Results of two parallel first-in-human phase I studies. Invest New Drugs 2015; 33: 679-90.
59. Kwegyir-Afful AK, Ramalingam S, Purushottamachar P, Ramamurthy VP, Njar VC. Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo. Oncotarget 2015; 6: 27440-60.
60. Montgomery B, Eisenberger MA, Rettig MB, Chu F, Pili R, et al. Androgen receptor modulation optimized for response (ARMOR) phase I and II studies: galeterone for the treatment of castration-resistant prostate cancer. Clin Cancer Res 2015; 22: 1356-63.
61. Golovine KV, Makhov PB, Teper E, Kutikov A, Canter D, et al. Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells. Prostate 2013; 73: 23-30.
62. Deep G, Raina K, Singh RP, Oberlies NH, Kroll DJ, et al. Isosilibinin inhibits advanced human prostate cancer growth in athymic nude mice: comparison with silymarin and silibinin. Int J Cancer 2008; 123: 2750-8.
63. Deep G, Oberlies NH, Kroll DJ, Agarwal R. Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway. Oncogene 2008; 27: 3986-98.
64. Itoh Y, Ishikawa M, Kitaguchi R, Sato S, Naito M, et al. Development of target protein-selective degradation inducer for protein knockdown. Bioorg Med Chem 2011; 19: 3229-41.
65. Huxley M, Sanchez-Cano C, Browning MJ, Navarro-Ranninger C, Quiroga AG, et al. An androgenic steroid delivery vector that imparts activity to a non-conventional platinum (II) metallo-drug. Dalton Trans 2010; 39: 11353-64.